ProNeurogen
Tucson, Arizona, United StatesSee on the mapFounded 2013
ProNeurogen is a biotechnology company developing peptide-based therapies to slow vascular dementia and help preserve cognitive function. Its Mas receptor agonist platform is designed to reduce neuroinflammation and support brain blood flow, with programs spanning neurovascular, neurodegenerative, and neuroinflammatory conditions.
- RaisedTotal raised
- $50M
- Investors
- 3
- Founded
- 2013
- Employees
- 2–10
reccy insights
ProNeurogen’s public profile centers on its Mas receptor agonist programs and a focus on cognitive impairment and vascular dementia. Its technology lineup includes PNA5, a glycosylated Angiotensin-(1-7) peptide, and PNA1, another Mas receptor agonist associated with human studies in traumatic brain injury and post-operative cognitive impairment. The available funding history includes a $4,008,872 grant in September 2019 and a $1,211,531 grant in August 2020, both listing HHS as a lead investor. Further grant activity includes $4,973,914 in September 2022 and $7,608,242 on September 18, 2023. These are historical milestones rather than newly announced developments. The company’s stated intellectual-property position includes five patent families covering Mas receptor analog compositions, formulations, and therapeutic uses, under an exclusive University of Arizona license.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes ProNeurogen distinct
- 01Focuses on therapies intended to slow vascular dementia and preserve cognitive function.
- 02Develops glycosylated Angiotensin-(1-7) peptides designed to selectively activate the Mas receptor.
- 03Targets inflammation and oxidative stress while aiming to support brain blood flow.
- 04Mas receptor biology supports potential applications across neurovascular, neurodegenerative, and neuroinflammatory disorders.
- 05Five patent families cover Mas receptor analog compositions, formulations, and therapeutic uses under an exclusive University of Arizona license.
Technology & products2
- PNA5
A glycosylated Angiotensin-(1-7) peptide and selective Mas receptor agonist being developed for vascular dementia and cognitive-function preservation.
- PNA1
A Mas receptor agonist associated with human studies in traumatic brain injury and post-operative cognitive impairment.
- PNA5, a glycosylated Angiotensin-(1-7) peptide and selective Mas receptor agonist.
- PNA1, a Mas receptor agonist associated with human studies in traumatic brain injury and post-operative cognitive impairment.
- A Mas receptor agonist platform for neuroprotection and cognitive function.
Research roots1
Labs and research groups this company came from or works with.
- No page yetUniversity of ArizonaTucson, United StatesTucson, United States · No page yetOther link
Recent updates2
- Aug 2026Award
August 2026 — NIH/NIA Awards $9 Million to Advance PNA5 into First-in-Human Clinical Testing
proneurogen.com - Aug 2026Award
NIH/NIA Awards $9 Million to Advance PNA5 into First-in-Human Clinical Testing
proneurogen.com
Funding
- Grant (prize money)Sep 2023$7.6M
- Federal GrantSep 2023$500K
- Grant (prize money)Sep 2022$5MLed by HHS
Investors1
About ProNeurogen
- Products
- PNA5, PNA1
- Leadership
- Meredith Hay
- Focus areas
- NeuroTechnology, biotech, therapeutics, pharmaceuticals, peptide therapeutics, vascular dementia, neuroscience, neuroinflammation
- Headquarters
- Tucson, Arizona, United States
- Founded
- 2013
- Employees
- 2–10
- Status
- Active · private